9457 related articles for article (PubMed ID: 19178659)
1. Cisplatin: a review of toxicities and therapeutic applications.
Barabas K; Milner R; Lurie D; Adin C
Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, a new antineoplastic drug in veterinary medicine.
Page R; Matus RE; Leifer CE; Loar A
J Am Vet Med Assoc; 1985 Feb; 186(3):288-90. PubMed ID: 3918977
[No Abstract] [Full Text] [Related]
4. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
5. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
6. Organo-platinum complexes as antitumor agents (review).
Hill JM; Speer RJ
Anticancer Res; 1982; 2(3):173-86. PubMed ID: 6751211
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms.
Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty M; Powers BE; Henkel SE; Withrow SJ
J Am Vet Med Assoc; 1993 Jun; 202(11):1845-8. PubMed ID: 8320153
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004).
Théon AP; Wilson WD; Magdesian KG; Pusterla N; Snyder JR; Galuppo LD
J Am Vet Med Assoc; 2007 May; 230(10):1506-13. PubMed ID: 17504043
[TBL] [Abstract][Full Text] [Related]
9. Comparison of perioperative versus postoperative intratumoral administration of cisplatin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses.
Théon AP; Pascoe JR; Galuppo LD; Fisher PE; Griffey SM; Madigan JE
J Am Vet Med Assoc; 1999 Dec; 215(11):1655-60. PubMed ID: 14567430
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
12. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
13. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).
Hewes CA; Sullins KE
J Am Vet Med Assoc; 2006 Nov; 229(10):1617-22. PubMed ID: 17107319
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of equine sarcoids with cisplatin in arachid oil: a useful alternative?].
Spoormakers TJ; Klein WR; van Weeren PR
Tijdschr Diergeneeskd; 2002 Jun; 127(11):350-4. PubMed ID: 12073779
[TBL] [Abstract][Full Text] [Related]
16. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity of chemotherapeutic agents.
Schweitzer VG
Otolaryngol Clin North Am; 1993 Oct; 26(5):759-89. PubMed ID: 8233488
[TBL] [Abstract][Full Text] [Related]
18. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity.
Chirino YI; Pedraza-Chaverri J
Exp Toxicol Pathol; 2009 May; 61(3):223-42. PubMed ID: 18986801
[TBL] [Abstract][Full Text] [Related]
19. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
20. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
Henry CJ; Flesner BK; Bechtel SA; Bryan JN; Tate DJ; Selting KA; Lattimer JC; Bryan ME; Grubb L; Hausheer F
J Vet Intern Med; 2018 Jan; 32(1):370-376. PubMed ID: 29080252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
